Profile data is unavailable for this security.
About the company
Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system. The Company's clinical assets focus on the modulation of cannabinoid receptor 1 (CB1) to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. Its Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion (SBI-100 OE), a CB1 agonist (activator), being developed for the treatment of glaucoma and ocular hypertension. The Company's Phase 2 study in obesity is designed to evaluate nimacimab's weight loss potential either as a single agent or in combination with a glucagon-like peptide-1 (GLP-1) agonist like semaglutide.
- Revenue in USD (TTM)0.00
- Net income in USD-37.64m
- Incorporated2011
- Employees11.00
- LocationSkye Bioscience Inc11250 EL CAMINO REAL, SUITE 100SAN DIEGO 92130United StatesUSA
- Phone+1 (858) 410-0266
- Fax+1 (775) 782-2611
- Websitehttps://skyebioscience.com/
More ▼
Mergers & acquisitions
| Acquired company | SKYE:NMQ since announced | Transaction value |
|---|---|---|
| Bird Rock Bio Inc | 228.79% | 15.50m |
Data delayed at least 15 minutes, as of May 03 2024 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ventyx Biosciences Inc | 0.00 | -192.96m | 341.92m | 79.00 | -- | 1.18 | -- | -- | -3.29 | -3.29 | 0.00 | 4.12 | 0.00 | -- | -- | 0.00 | -59.46 | -- | -63.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.97 | -- | -- | -- |
| Ocugen Inc | 6.04m | -63.08m | 342.24m | 65.00 | -- | 8.41 | -- | 56.70 | -0.2616 | -0.2616 | 0.0247 | 0.1581 | 0.0697 | -- | -- | 92,861.54 | -72.85 | -83.56 | -91.66 | -97.79 | -- | -- | -1,045.03 | -2,921.94 | -- | -- | 0.0646 | -- | 142.60 | -- | 27.33 | -- | 39.08 | -- |
| Terns Pharmaceuticals Inc | 0.00 | -90.21m | 351.83m | 66.00 | -- | 1.38 | -- | -- | -1.27 | -1.27 | 0.00 | 3.95 | 0.00 | -- | -- | 0.00 | -32.48 | -41.34 | -33.72 | -45.70 | -- | -- | -- | -31,010.30 | -- | -- | 0.00 | -- | -- | -- | -49.49 | -- | -26.60 | -- |
| Precigen Inc | 6.23m | -95.90m | 353.47m | 202.00 | -- | 2.98 | -- | 56.78 | -0.3933 | -0.3933 | 0.0255 | 0.476 | 0.0339 | -- | 6.62 | 30,816.83 | -52.26 | -31.50 | -72.27 | -38.63 | 1.70 | 44.00 | -1,540.63 | -232.32 | -- | -- | 0.00 | -- | -76.87 | -47.16 | -20.22 | -- | -48.30 | -- |
| Nature's Sunshine Products Inc | 445.32m | 15.08m | 358.69m | 814.00 | 24.71 | 2.34 | 12.71 | 0.8055 | 0.7715 | 0.7715 | 22.78 | 8.16 | 1.86 | 1.84 | 38.84 | 547,076.20 | 6.85 | 6.57 | 10.02 | 9.41 | 72.11 | 72.69 | 3.69 | 3.74 | 1.29 | -- | 0.00 | 27.72 | 5.55 | 4.07 | 3,965.64 | -- | 16.73 | -- |
| Rani Therapeutics Holdings Inc | 0.00 | -33.97m | 360.47m | 140.00 | -- | 26.20 | -- | -- | -1.33 | -1.33 | 0.00 | 0.2729 | 0.00 | -- | -- | 0.00 | -81.81 | -- | -131.29 | -- | -- | -- | -- | -- | -- | -37.05 | 0.5359 | -- | -- | -- | -11.06 | -- | -- | -- |
| Skye Bioscience Inc | 0.00 | -37.64m | 365.38m | 11.00 | -- | -- | -- | -- | -5.69 | -5.69 | 0.00 | -0.1726 | 0.00 | -- | -- | 0.00 | -357.65 | -232.67 | -- | -- | -- | -- | -- | -- | -- | -43.27 | 1.95 | -- | -- | -- | -93.23 | -- | 23.38 | -- |
| Black Diamond Therapeutics Inc | 0.00 | -82.44m | 365.61m | 54.00 | -- | 3.08 | -- | -- | -1.92 | -1.92 | 0.00 | 2.26 | 0.00 | -- | -- | 0.00 | -52.37 | -40.29 | -58.91 | -43.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.57 | -- | -15.37 | -- |
| Harrow Inc | 130.19m | -24.41m | 367.26m | 315.00 | -- | 5.16 | -- | 2.82 | -0.7448 | -0.7448 | 3.99 | 2.01 | 0.5546 | 4.55 | 6.13 | 413,311.10 | -10.40 | -10.86 | -12.14 | -12.71 | 69.55 | 70.75 | -18.75 | -15.35 | 2.61 | 0.0445 | 0.7223 | -- | 46.95 | 25.77 | -73.30 | -- | 143.88 | -- |
| Tenaya Therapeutics Inc | 0.00 | -124.08m | 367.46m | 140.00 | -- | 2.29 | -- | -- | -1.68 | -1.68 | 0.00 | 2.04 | 0.00 | -- | -- | 0.00 | -55.21 | -- | -61.66 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.3388 | -- | -- | -- |
| Contineum Therapeutics Inc | 50.00m | 22.72m | 368.62m | 31.00 | 15.59 | -- | 16.06 | 7.37 | 0.9041 | 0.9041 | 1.99 | 4.96 | -- | -- | -- | 1,612,903.00 | -- | -- | -- | -- | -- | -- | 45.44 | -- | -- | -- | 0.00 | -- | -- | -- | 193.68 | -- | -- | -- |
| Jasper Therapeutics Inc | 0.00 | -64.47m | 369.90m | 45.00 | -- | 3.49 | -- | -- | -6.19 | -6.19 | 0.00 | 7.03 | 0.00 | -- | -- | 0.00 | -90.00 | -- | -104.13 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.06 | -- | -- | -- |
| Erasca Inc | 0.00 | -125.04m | 370.99m | 126.00 | -- | 1.02 | -- | -- | -0.8327 | -0.8327 | 0.00 | 2.10 | 0.00 | -- | -- | 0.00 | -27.48 | -- | -29.94 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.50 | -- | -- | -- |
| Amarin Corporation plc (ADR) | 277.46m | -52.61m | 373.71m | 275.00 | -- | 0.6846 | -- | 1.35 | -0.1288 | -0.1288 | 0.679 | 1.33 | 0.3363 | 0.4197 | 2.23 | 1,008,927.00 | -6.38 | -4.48 | -8.90 | -6.54 | 63.61 | 75.70 | -18.96 | -8.59 | 1.93 | -- | 0.00 | -- | -16.87 | 6.01 | 44.13 | -- | 55.83 | -- |
| Alto Neuroscience Inc | 0.00 | -36.31m | 382.29m | 63.00 | -- | -- | -- | -- | -1.42 | -1.42 | 0.00 | 2.73 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.1238 | -- | -- | -- | -31.02 | -- | -- | -- |
| Solid Biosciences Inc | 0.00 | -96.02m | 382.39m | 88.00 | -- | 1.63 | -- | -- | -4.84 | -4.84 | 0.00 | 6.20 | 0.00 | -- | -- | 0.00 | -45.16 | -49.99 | -49.47 | -56.25 | -- | -- | -- | -2,117.05 | -- | -- | 0.0133 | -- | -100.00 | -- | -11.67 | -- | -27.90 | -- |
Data as of May 03 2024. Currency figures normalised to Skye Bioscience Inc's reporting currency: US Dollar USD
9.28%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Altium Capital Management LPas of 29 Jan 2024 | 1.30m | 4.64% |
| Sphera Funds Management Ltd.as of 29 Jan 2024 | 1.30m | 4.64% |
| Bankinter Gesti�n de Activos SA SGIICas of 31 Dec 2023 | 0.00 | 0.00% |
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
